Clinical Trial

H101 Plus TACE for r/m HNSCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-19
notable Primary completion pushed: 2027-02-15 -> 2028-06-15 2026-07-19
minor Completion pushed: 2028-02-15 -> 2028-12-15 2026-07-19
Trial Details
NCT Number NCT07398664
Lead Sponsor West China Hospital
Conditions Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
Enrollment 20 participants
Start Date 2026-03-02
Primary Completion 2028-06-15 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-17